Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: Technical advantages using computer-assisted gamma probe with adjustable collimation

Melanoma Research

Volumn 14, Issue 4, 2004, Pages 311-319

  Borgognoni, Lorenzo ^a   Urso, Carmelo ^a   Vaggelli, Luca ^b   Brandani, Paola ^a   Gerlini, Gianni ^a   Reali, Umberto Maria ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Interval nodes; Melanoma; Probe; Prognosis; Recurrences; Sentinel node

Indexed keywords

DYE; TECHNETIUM 99M;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; MELANOMA; MIDDLE AGED; NEOPLASTIC PROCESSES; PROGNOSIS; RECURRENCE; SENTINEL LYMPH NODE BIOPSY; SPECTRUM ANALYSIS; SURVIVAL RATE;

EID: 4344596703     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000133968.28172.6e     Document Type: Article

References (45)

1. Chao C, McMasters KM. Update on the use of sentinel node biopsy in patients with melanoma: who and how. Current Opin Oncol 2002; 14: 217-220.
2. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 11:2851-2855.
3. Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma: past, present, and future. Ann Surg Oncol 2001; 8 (9 suppl):22S-28S.
4. Morton DL, Chan AD. The concept of sentinel node localization: how it started. Semin Nucl Med 2000; 30:4-10.
5. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
6. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
7. Eggermont AMM. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer Res 2000; 157:178-189.
8. Cochran AJ. The pathologist's role in sentinel lymph node evaluation. Semin Nucl Med 2000; 30:11-17.
9. Baisden BL, Askin FB, Lange JR, Westra WH. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol 2000; 24:1140-1146.
10. Vaggelli L, Castagnoli A, Borgognoni L, Urso C, Matteini M, Cesco P. Radioisotopic lymphatic mapping of the sentinel node in melanoma: importance of immunohistochemistry. Tumori 2000; 86:346-348.
11. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm KF, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
12. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 1993; 2:303-308.
13. Van Der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994; 81:1769-1770.
14. Krag DN, Sybren JM, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130:654-658.
15. Vidal-Sicart S, Pons F, Puig S, Onega M, Vilalta A, Martin F, et al. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging 2003; 30:362-366.
16. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes - one institution's experience. Melanoma Res 2003; 13: 35-43.
17. Belhocine T, Pierard GE, Gielen JL, Daenen F, De Barsy C, Arrese JE, et al. Gamma-probe-directed lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma. Dermatology 2002; 204:355-361.
18. Doting MH, Hoekstra HJ, Plukker JT, Piers DA, Jager PL, Tiebosch AT, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol 2002; 28: 673-678.
19. Harlow SP, Krag DN, Ashikaga, Weaver DL, Meijer SJ, Loggie BW, et al. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res 2001; 11:45-55.
20. Statius Muller MG, Leeuwen PAM, Diest PJ, Vuylsteke RJCLM, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 2001; 11:303-307.
21. Thompson JF, Uren RF. What is a 'sentinel' lymph node? Eur J Surg Oncol 2000; 26:103-104.
22. Thompson JF, McCarthy WH, Bosch MJ, O'Brien CJ, Quinn MJ, Paramaesvaran S, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5:255-260.
23. Glass LF, Messina JL, Cruse W, Wells K, Rappaport D, Miliotes G, et al. The use of intraoperative radiolymphoscintigraphy for sentinel node biopsy in patients with malignant melanoma. Dermatol Surg 1996; 22: 715-720.
24. Bostick PJ, Essner R, Glass E, Kelley M, Sarantou T, Foshag LJ, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999; 134:43-49.
25. Bostick PJ, Giuliano AE. Vital dyes in sentinel node localization. Semin Nucl Med 2000; 30:18-24.
26. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, et al. Sentinel node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol 2001; 8:192-197.
27. Jacobs IA, Chang CK, DasGupta TK, Salti G. High isotope counts and sentinel node positivity in patients with melanoma. Arch Surg 2003; 138:63-66.
28. Leong SPL, Steinmetz I, Habib FA, McMillan A, Gans JZ, Allen RE, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997; 132:666-673.
29. Kapteijn BAE, Nieweg OE, Liem IH, Mooi WJ, Balm AJM, Muller SH, et al. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997; 4:156-160.
30. Testori A, Bartolomei M, Grana C, Mezzetti M, Chinol M, Mazzarol G, et al. Sentinel node localization in primary melanoma: learning curve and results. Melanoma Res 1999; 9:587-593.
31. Pijpers R, Borgstein PJ, Teule GJ, Meijers S. Vital dye and radiolabelled colloids: complement or alternative? Recent Results Cancer Res 2000; 157:130-137.
32. Coit DG. The 'true' sentinel lymph node: in search of an operational definition of a biological phenomenon. Ann Surg Oncol 2001; 8:187-189.
33. Uren RF, Howman-Giles R, Thompson JF, McCarthy WH, Quinn MJ, Roberts JM, Shaw HM. Interval node: the forgotten sentinel nodes in patients with melanoma. Arch Surg 2000; 135:1168-1172.
34. Roozendaal GK, de Vries JDK, van Poll D, Jansen L, Schraffordt KH, Nieweg OE, Kroon BB. Sentinel nodes outside lymph node basins in patients with melanoma. Br J Surg 2001; 88:305-308.
35. Thelmo MC, Morita ET, Tresler PA, Nguyen LH, Allen RE, Sagabiel RW, et al. Micrometastasis to in-transit lymph nodes from extremity and truncal malignant melanoma. Ann Surg Oncol 2001; 8:444-448.
36. Thompson JF, Hunt JA, Culjak G, Uren RF, Howman-Giles R, Harman CR. Popliteal lymph node metastasis from primary cutaneous melanoma. Eur J Surg Oncol 2000; 26:172-176.
37. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253-2260.
38. Temple CL, Scilley CG, Engel CJ, Hum DT, Lohmann RC, Mattar AG, Zable PL. Sentinel node biopsy in melanoma using technetium-99m rhenium colloid: the London experience. Ann Plast Surg 2000; 45:491-499.
39. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001; 233:250-258.
40. Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg 2003; 112:486-497.
41. Reintgen D, Albertini J, Miliotes G, Berman C, Cruse CW, Fenske N, et al. The accurate staging and modern day treatment of malignant melanoma. Cancer Res Ther Control 1995; 4:183-197.
42. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patients with malignant melanoma. Ann Surg 1997; 225:1-14.
43. Hatta N, Fujjimoto A, Takehara K, Takata M. Mapping of occult melanoma micrometastases in the inguinal lymph node basin by immunohistochemistry and RT-PCR. Melanoma Res 1999; 9:401-406.
44. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-983.
45. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early stage melanoma: a multicenter trial - Multicenter Lymphadenectomy Trial Group. Ann Surg 1999; 230:453-463.